Massive blow to cardiology
A highly anticipated cholesterol drug failed to show any measurable benefit to heart patients in a clinical trial

The ‘slam dunk’ that wasn’t: Promising cholesterol drug fails to prevent heart attacks or stroke
The drug, Novartis’ pelacarsen, should have worked against lipoprotein(a), a genetic type of cholesterol that causes plaque to build up in arteries, researchers said. Why didn’t it?











